Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.

Weiden, Peter J; Breier, Alan; Kavanagh, Sarah; Miller, Andrew C; Brannan, Stephen K; Paul, Steven M

Weiden, Peter J; Breier, Alan; Kavanagh, Sarah; Miller, Andrew C; Brannan, Stephen K; Paul, Steven M.

Afiliação

Weiden PJ; Karuna Therapeutics, Boston, Massachusetts.
Breier A; Corresponding author: Peter J. Weiden, MD, Karuna Therapeutics, 99 High St, Floor 26, Boston, MA 02110 (pweiden@karunatx.com).
Kavanagh S; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana.
Miller AC; Kavanagh Statistical Consulting, Apex, North Carolina.
Brannan SK; Karuna Therapeutics, Boston, Massachusetts.
Paul SM; Karuna Therapeutics, Boston, Massachusetts.

J Clin Psychiatry ; 83(3)2022 05 11.

Article em En | MEDLINE | ID: mdl-35552528

Assuntos

Piridinas; Esquizofrenia; Tiadiazóis; Antipsicóticos/uso terapêutico; Método Duplo-Cego; Humanos; Piridinas/uso terapêutico; Esquizofrenia/tratamento farmacológico; Tiadiazóis/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridinas / Esquizofrenia / Tiadiazóis Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google